SCHEMBL4840798

SCHEMBL4840798

CC(C)(C)OC(=O)CC(CC(=O)NOC(c1ccccc1)(c1ccccc1)c1ccccc1)C(=O)NCCc1ccc(-c2ccc(O)cc2)cc1

nearest known ligand 0.45

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 6/20 0.45
MMP9 P14780 2/20 0.45
MMP8 P22894 2/20 0.45
ESRRG P62508 5/20 0.41
ESRRB O95718 3/20 0.41
CA2 P00918 2/20 0.41
CA9 Q16790 1/20 0.40
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
GLI1 P08151 1/20 0.38
GLI2 P10070 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.37
MMP3 P08254 3/20 0.37
NR1H2 P55055 1/20 0.37
HRH3 Q9Y5N1 1/20 0.36
MMP1 P03956 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4839942 0.95 CA2 (0.45) MMP2MMP9MMP8ESRRGCA2
SCHEMBL4841261 0.91 ABCB1 (0.46) MMP2MMP9MMP8ESRRGCA2
SCHEMBL4840314 0.91 CA2 (0.40) MMP2MMP9MMP8ESRRGCA2
SCHEMBL4835699 0.88 SMN1; SMN2 (0.43) CA2CA9NPC1RAB9A
SCHEMBL4831392 0.88 CA2 (0.43) MMP2MMP9MMP8ESRRGCA2
SCHEMBL4838858 0.87 CA2 (0.39) ESRRGCA2CA9NPC1RAB9A
SCHEMBL4831283 0.86 CA2 (0.49) MMP9MMP8CA2CA9NPC1
SCHEMBL4886128 0.85 KMT2A (0.45) MMP2CA2CA9MMP3
SCHEMBL6253965 0.84 MMEL1 (0.51) MMP2MMP9MMP8ESRRGCA2
SCHEMBL4841231 0.81 MMEL1 (0.54) MMP2MMP9MMP8ESRRGCA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7365091-B2 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of PHEX ENOBIA PHARMA (CA) 2008-04-29 US disclosed
US-20060287280-A1 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of PHEX ENOBIA PHARMA (CA) 2006-12-21 US disclosed
US-7105539-B2 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex ENOBIA PHARMA (CA) 2006-09-12 US disclosed
US-20060135480-A1 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex ENOBIA PHARMA (CA) 2006-06-22 US disclosed
EP-1572645-A2 DERIVATIVES OF SUCCINIC AND GLUTARIC ACIDS AND ANALOGS THEREOF USEFUL AS INHIBITORS OF PHEX Enobia Pharma Inc. (CA) 2005-09-14 EP disclosed
US-20040186301-A1 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex BIOMEP INC. 2004-09-23 US disclosed
WO-2004050620-A2 DERIVATIVES OF SUCCINIC AND GLUTARIC ACIDS AND ANALOGS THEREOF USEFUL AS INHIBITORS OF PHEX ENOBIA PHARMA (CA) 2004-06-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060287280-A1 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of PHEX GLS, SUCNR1, PGD MMP2 2325/4885MMP9 3110/4885MMP8 4356/4885
US-20040186301-A1 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex GLS, SUCNR1, PGD MMP2 2359/4885MMP9 3196/4885MMP8 4395/4885
US-20060135480-A1 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex GLS, SUCNR1, GCDH MMP2 2347/4885MMP9 3234/4885MMP8 4405/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.